Most recurrent ovarian cancer cases arise in patients previously treated with PARP inhibitors making these results noteworthy ...
King’s College London researchers discovered that parts of our DNA once thought to be “junk” can actually help destroy cancer ...
The PARP Inhibitors Market Size is valued at USD 3.8 Billion in 2024 and is predicted to reach USD 15.5 Billion by the year 2034 at a 15.2% CAGR during the forecast period for 2025-2034. Poly ...
The presentation will feature the first clinical results for ART6043 from the Phase 1/2a study ( NCT05898399 ), including safety, tolerability, pharmacokinetics, and preliminary efficacy in patients ...
Avacta Therapeutics (AIM: AVCT, ‘Avacta’, ‘the Company’), a clinical stage biopharmaceutical company developing pre|CISION ®, a tumor-activated oncology delivery platform, today announced the ...
Chemotherapy may soon take a backseat. Experts say targeted therapies—drugs that attack cancer at the genetic level—are ...
Nanoform Finland Plc | Press Release | October 27, 2025 at 09:10:00 EET Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced a partnership ...
Merck reports phase 3 KEYNOTE-B96 trial meets secondary endpoint of OS in all comers population of patients with platinum-resistant recurrent ovarian cancer: Rahway, New Jersey Sa ...
The platinum-resistant ovarian cancer market is expanding due to a growing unmet need, as many patients relapse after first-line platinum therapies, driving demand for novel second- and later-line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback